Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Other Non-Current Assets (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Other Non-Current Assets for 12 consecutive years, with $210000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets rose 60.31% year-over-year to $210000.0, compared with a TTM value of $210000.0 through Sep 2025, up 60.31%, and an annual FY2024 reading of $131000.0, changed 0.0% over the prior year.
  • Other Non-Current Assets was $210000.0 for Q3 2025 at Avalo Therapeutics, roughly flat from $210000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.0 million in Q4 2021 and bottomed at $131000.0 in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $204736.8, with a median of $131000.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Assets surged 571.14% in 2021, then plummeted 86.9% in 2022.
  • Year by year, Other Non-Current Assets stood at $1.0 million in 2021, then tumbled by 86.9% to $131000.0 in 2022, then changed by 0.0% to $131000.0 in 2023, then changed by 0.0% to $131000.0 in 2024, then skyrocketed by 60.31% to $210000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for AVTX at $210000.0 in Q3 2025, $210000.0 in Q2 2025, and $131000.0 in Q1 2025.